View printer-friendly version << Back

Novavax to Host 2nd Annual Analyst and Investor Meeting

GAITHERSBURG, Md., Sept. 11, 2014 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced that it will host its 2nd annual Analyst and Investor Meeting to be held on Tuesday, September 23, 2014 from 9:00 a.m.11:00 a.m. (ET) in New York, NY.

Senior management will conduct a series of presentations to update analysts and investors as to the company's recombinant nanoparticle vaccine technology, its RSV program, and its influenza program.

For additional information and registration, please e-mail, or call 443-213-0506.

A live webcast link of the presentations will be available via the company website at under Investor Info/Events. Please allow extra time prior to the webcast to visit the site and download the streaming media software required to listen to the Internet broadcast. The event will be archived on the company's website for 90 days.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating vaccines and vaccine adjuvants to address a broad range of infectious diseases worldwide. Using innovative proprietary recombinant nanoparticle vaccine technology, the company produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases.

CONTACT: Barclay A. Phillips
         SVP, Chief Financial Officer and Treasurer
         Novavax, Inc.

Novavax logo

Novavax, Inc.

This site uses cookies and similar technologies to provide you with our services, enhance the performance and functionality of our services, and analyze the use of our products and services. By clicking ‘Accept’ you are indicating your consent for us to place these cookies. For more information, please read our Privacy Policy or manage your cookie settings.